ipharmacenter Consulting services

Bristol Myers Squibb Bristol Myers Squibb Unveils Promising Sotyktu Results for Psoriatic Arthritis and Lupus at ACR Conference Bristol Myers Squibb has unveiled new data from late-breaking clinical studies highlighting the promise of Sotyktu (deucravacitinib) in treating both psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE). These findings, from the pivotal Phase 3 POETYK PsA-1 trial and integrated Phase 2 PAISLEY-SLE and long-term extension studies. Psoriati

PFIZER Xtandi Plus Leuprolide Cuts Risk of Death by 40% in Advanced Prostate Cancer, Delivering Unprecedented 8-Year Survival Benefit Pfizer and Astellas have announced final overall survival (OS) results from the Phase 3 EMBARK trial, revealing that Xtandi (enzalutamide) in combination with leuprolide significantly prolonged survival in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) who had high-risk biochemical recurrence (BCR). Major Survival Advantage